Business

Zydus Lifesciences gets USFDA nod to market generic drugs

February 28, 2026

Zydus Lifesciences has received approval from the USFDA to market generic versions of Ivermectin and Dapsone tablets, expanding its offerings in the treatment of parasitic infections and leprosy. The approvals include Ivermectin Tablets (3 mg) and Dapsone Tablets (25 mg and 100 mg), which are essential for treating specific infections and conditions.

Zydus Lifesciences gets USFDA nod to market generic drugs

Credit: Dailyexcelsior

Key Highlights

Zydus Lifesciences received USFDA approval for generic Ivermectin and Dapsone tablets.
Ivermectin tablets are indicated for treating intestinal strongyloidiasis and onchocerciasis.
Dapsone tablets are used for the treatment of leprosy and dermatitis herpetiformis.
Ivermectin is a prescription anti-parasitic medication.
Dapsone acts as an anti-infective and antibacterial agent.

Business

Sources

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

Zydus Lifesciences gets USFDA nod to market generic drugs

Key Highlights

Sources

Related Stories

Royal Enfield sales up 11 pc at 1,00,905 units in Feb

Adani confirms Israel-based Haifa Port fully secure, operational

Govt to take consensual view before implementing new fuel emission norms...